Hanover

28 Mar 2022

Hanover has today announced that former NHS England medicines adviser Malcolm Qualie has joined Hanover as a Senior Advisor focused on market access.

From 2013 until January 2022, Malcolm was Medicines Lead for Specialised Commissioning at NHS England.

Malcolm Qualie will support clients to understand the NHS environment as the health system seeks to agree more deals with companies on innovative therapies.

Malcolm joins Hanover’s market access team alongside former NICE Highly Specialised Technology lead Josie Godfrey to bring senior advisory counsel across the HTA and commissioning landscape.

The best medicines access and service developments should be a win-win partnership between the NHS or health system and industry to deliver better outcomes for patients. I am looking forward to helping clients understand how to engage successfully in today’s environment.

Hanover Health has a European and international market access practice supporting clients to prepare successfully for launch with a wider suite of in-house expertise and advisors including former payers, regulators, industry execs and health system managers from a range of major markets.

In England, successful access for rare and specialised therapies increasingly relies on deals with NHS England alongside NICE approval. The Government’s Life Sciences Vision has stated a desire for more innovative deals which has further increased global biopharma interest in access and uptake approaches in England.

Companies are looking to understand how to engage successfully in this environment – which access pathways are best suited for their pipeline asset, what flexibilities exist for new innovative deals, and how to best prepare. This requires a new market access approach beyond traditional HEOR. Hanover’s suite of senior advisers together with its own policy, access, and communications expertise provides insight and engagement strategies in this fast-changing environment.

Malcolm Qualie said: “The best medicines access and service developments should be a win-win partnership between the NHS or health system and industry to deliver better outcomes for patients. I am looking forward to helping clients understand how to engage successfully in today’s environment.”

Andrew Harrison, Group MD of Hanover Health said: “In the UK and internationally, health system payers and companies are exploring how to develop innovative deals and agreements to bring specialised and complex therapies to patients. Malcolm brings unparalleled expertise to our market access offer in this fast moving and important area for clients.”

Hanover has developed a robust access framework to assess the need and suitability of company pipeline assets for innovative value-based agreements (VBAs). Malcolm and Josie’s experience from NHS England and NICE will further bolster these capabilities and offer companies the opportunity to stress test their offer prior to engaging with the NHS.